FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR

Human lung adenocarcinomas with activating mutations in EGFR (epidermal growth factor receptor) often respond to treatment with EGFRtyrosine kinase inhibitors(TKIs),butthe magnitude of tumour regression is variable and transient(1,2). This heterogeneity in treatment response could result from geneti...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Bivona, Trever G., Hieronymus, Haley, Parker, Joel, Chang, Kenneth, Taron, Miquel, Rosell, Rafael, Moonsamy, Philicia, Dahlman, Kimberly, Miller, Vincent A., Costa, Carlota, Hannon, Gregory, Sawyers, Charles L.
Formato: Artigo
Idioma:Inglês
Publicado: 2011
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC3541675/
https://ncbi.nlm.nih.gov/pubmed/21430781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature09870
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares